Reviva’s Schizophrenia Therapeutic On Track to Change Lives
Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) has evaluated the last patient in its global pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia. More than 24 million people worldwide are living with schizophrenia, which is characterized by delusions, hallucinations, disorganized thinking and abnormal motor behavior.
Laxminarayan Bhat, Ph.D., Founder, President and CEO of Reviva, said, “Brilaroxazine is designed to overcome critical gaps in current therapies by offering a well-tolerated safety profile favorable for long-term use, and by addressing the positive, negative, mood, and cognitive symptoms and neuroinflammation associated with schizophrenia.”
Reviva expects to report pivotal topline data this October.
Highlights
Brilaroxazine is a serotonin-dopamine stabilizer with multifaceted activity designed to improve schizophrenia symptoms and accompanying neuroinflammation.
RECOVER is a global Phase 3, randomized, double-blind, placebo-controlled, multicenter study designed to assess the safety and efficacy of brilaroxazine in 410 patients with acute schizophrenia compared to placebo.
In a multinational, multicenter, double-blind Phase 2 study in 234 patients with acute schizophrenia or schizoaffective disorder, brilaroxazine met its primary and secondary endpoints evaluating social functioning, and positive and negative symptoms, and directional improvements for depression and cognition.
About Reviva Pharmaceuticals
Reviva is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and RP1208 in the United States (U.S.), Europe, and several other countries.
